Skip to content

Recursion Pharmaceuticals, Inc. RXRX Indefinite-Lived Intangible Assets

Indefinite-Lived Intangible Assets at other companies

Wingstop logo
WingstopWING
$32.7M0.0%
STU
StubHub Holdings, Inc.STUB
$864.8M
Resideo Technologies, Inc. logo
Resideo Technologies, Inc.REZI
$180M
UFP Industries, Inc. logo
UFP Industries, Inc.UFPI
$7.35M+0.6%
JBT Marel Corporation logo
JBT Marel CorporationJBTM
$11M+5.8%
Caesars Entertainment, Inc. logo
Caesars Entertainment, Inc.CZR
$3.26B-0.7%

Other financials

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation

See full
Market cap$1.71B-23.7%
Enterprise value$1.14B-39.8%
P/S25.8×-11.8×

Profitability

See full
Gross margin7.2%
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets?
Recursion Pharmaceuticals, Inc. (RXRX) reported indefinite-lived intangible assets of $135.55M in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets changed year-over-year?
Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets increased by 2.1% year-over-year, from $132.74M to $135.55M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets?
Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s indefinite-lived intangible assets has grown at a 173.4% compound annual growth rate (CAGR), from $904K to $138.02M.
What does indefinite-lived intangible assets mean?
This represents intangible assets, such as iconic brand names or trademarks, that are expected to generate cash flows for an unlimited period. Unlike finite-lived assets, these are not amortized but are tested annually for impairment. They represent the core long-term value of the company's brand portfolio.